Fractionated 131I anti-CEA radioimmunotherapy: Effects on xenograft tumour growth and haematological toxicity in mice

British Journal of Cancer

Volumn 99, Issue 4, 2008, Pages 632-638

  Violet, J A ^a   Dearling, J L J ^a   Green, A J ^a   Begent, R H J ^a   Pedley, R B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

131I; Anti CEA antibody targeting; CFUgm; Colorectal cancer; Dose fractionation; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN I 131; IODINE 131; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; COLONY FORMING UNIT; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; THERAPY EFFECT; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT; WEIGHT; ADENOCARCINOMA; ANIMAL; BONE MARROW; CELL CULTURE; CLONOGENIC ASSAY; COLORECTAL TUMOR; DRUG SCREENING; HEMATOLOGIC DISEASE; IMMUNOLOGY; METASTASIS; PATHOLOGY; RADIATION EXPOSURE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW; CARCINOEMBRYONIC ANTIGEN; COLONY-FORMING UNITS ASSAY; COLORECTAL NEOPLASMS; DOSE FRACTIONATION; FEMALE; GRANULOCYTES; HEMATOLOGIC DISEASES; HUMANS; IODINE RADIOISOTOPES; MACROPHAGES; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49549094264     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604511     Document Type: Article

References (37)

1. Beaumier PL, Venkatesan P, Vanderheyden JL, Burgua WD, Kunz LL, Fritzberg AR, Abrams PG, Morgan ACJ (1991) 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 51: 676-681
2. Begent RH, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, Keep PA, Adam T, Dale RG, Glaser MG (1989) Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer 60: 406-412
3. Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R (2005a) Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody. Clin Cancer Res 11(19 Part 2): 7070s-7074s
4. Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R (2005b) Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody. Clin Cancer Res 11(19 Part 2): 7070s-7074s
5. Blumenthal RD, Kashi R, Sharkey RM, Goldenberg DM (1995) Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer 61: 557-566
6. Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM (1991) Suppression of tumor vascular activity by radioantibody therapy: implications for multiple cycle treatments. Sel Cancer Ther 7: 9-16
7. Blumenthal RD, Sharkey RM, Kashi R, Sides K, Stein R, Goldenberg DM (1997) Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts. Tumour Biol 18: 367-377
8. Buchsbaum DJ, Khazaeli MB, Liu TP, Bright S (1995) Fractionated radioimmunotherapy of human colon cancer xenografts with I-131 labelled monoclonal antibody CC49. Cancer Res 55(Suppl): 5881-5887
9. 131I-labeled CC49 for therapy in a colon cancer xenograft model. Clin Cancer Res 5(10 Suppl): 3153s-3159s
10. Burke JM, Jurcic JG, Scheinberg DA (2002) Radioimmunotherapy for acute leukemia. (Review) (42 refs). Cancer Control 9: 106-113
11. Chu-Tse W, Lajtha LG (1975) Haemopoietic stem-cell kinetics during continuous irradiation. Int J Radiat Biol Relat Stud Phys Chem Med 27: 41-50
12. Dale RG (1996) Dose-rate effects in targeted radiotherapy. (Review) (46 refs). Phys Med Biol 41: 1871-1884
13. Dale RG (1985) The application of the linear-quadratic dose effect equation to fractionated and protracted radiotherapy. Br J Radiol 58: 515-528
14. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ (2002) Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94(4 Suppl): 1332-1348
15. DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, Goldstein DS, Mirick GR, Salako Q, Mausner LF, Srivastava SC, Meares CF (1999) 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 40: 302-310
16. Fowler JF (1990) Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 18: 1261-1269
17. 131I-labeled multivalent CC49 single-chain fvs. Clin Cancer Res 7: 175-184
18. Greenwood FC, Hunter WM (1963) The Preparation of 131I-Labelled human growth hormone of high specific radioactivity. Biochem J 89: 116-123
19. Hall EJ (1985) Radiation biology. Cancer 55: 2051-2057
20. Hendry JH, Lajtha LG (1972) The response of hemopoietic colony-forming units to repeated doses of X-rays. Radiat Res 52: 309-315
21. Hendry JH, Lord BI (1983) The analysis of the early and late response to cytotoxic insults in the haematopoetic cell hierarchy. In: Cytotoxic Injury to Tissue, Potten CS, Hendry JH (eds), Churchill Livingstone: Edinburgh, UK, p 1
22. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259-1266
23. Koppe MJ, Bleichrodt RP, Oyen WJ, Boerman OC (2005) Radioimmunotherapy and colorectal cancer. (Review) (86 refs). Br J Surg 92: 264-276
24. Lane DM, Eagle KF, Begent RH, Hope-Stone LD, Green AJ, Casey JL, Keep PA, Kelly AM, Ledermann JA, Glaser MG (1994) Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab0)2 antibodies. Br J Cancer 70: 521-525
25. Langmuir VK, Sutherland RM (1988) Radiobiology of radioimmunotherapy. Antibody, Immunoconjugate, Radiopharmaceutical 1: 195-211
26. Looney WB, Mayo AA, Allen PM, Morrow JY, Morris HP (1973) A mathematical evaluation of tumour growth curves in rapid, intermediate and slow growing rat hepatomata. Br J Cancer 27: 341-344
27. Pedley RB, Begent RH, Boden JA, Boden R, Adam T, Bagshawe KD (1991) The effect of radiosensitizers on radio-immunotherapy, using 131I-labelled anti-CEA antibodies in a human colonic xenograft model. Int J Cancer 47: 597-602
28. Pedley RB, Begent RH, Boden JA, Boxer GM, Boden R, Keep PA (1994) Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model. Int J Cancer 57: 830-835
29. Pedley RB, Boden JA, Boden R, Dale R, Begent RH (1993) Comparative radioimmunotherapy using intact or F(ab0)2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer 68: 69-73
30. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH (2001) Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 61: 4716-4722
31. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336-340
32. Roberson PL, Dudek S, Buchsbaum DJ (1997) Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. Cancer 80: 2567-2575
33. Rogers GT, Rawlins GA, Kardana A, Gibbons AR, Bagshawe KD (1984) A monoclonal antibody against a CEA-related antigen expressed on HT29 colon tumour cells. Eur J Cancer Clin Oncol 20: 1279-1286
34. Schlom J, Molinolo A, Simpson JF, Siler K, Roselli M, Hinkle G, Houchens DP, Colcher D (1990) Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82: 763-771
35. Testa NG, Hendry JH, Lajtha LG (1974) The response of mouse haematopoetic colony-forming units to repeated whole-body X irradiation. Biomedicine (Express) 21: 431
36. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD (1976) Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 12: 180-191
37. Vriesendorp HM, Shao Y, Blum JE, Quadri SM, Williams JR (1993) Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl Med Biol 20: 571-578